Showing results (141-150 of 163) with videos related to

Sort By:
Pageof 17
Heart, Lung & Circulation|July 1, 2026
Diabetes and Risk of Radial Artery Occlusion After Distal Radial Access: Insights From the KODRA RegistryByung Gyu Kim, Hyun Cho, Sung Eun Kim, et al.
European Heart Journal|May 15, 2024
Ticagrelor monotherapy for acute coronary syndrome: an individual patient data meta-analysis of TICO and T-PASS trialsYong-Joon Lee, Sanghoon Shin, Sung Woo Kwon, et al.
American Heart Journal|July 31, 2013
Study design and rationale of "a multicenter, open-labeled, randomized controlled trial comparing three 2nd-generation drug-eluting stents in real-world practice" (CHOICE trial)Young Jin Youn, Jun-Won Lee, Sung Gyun Ahn, et al.
Korean Circulation Journal|January 22, 2020
Safety and Efficacy of a New Ultrathin Sirolimus-Eluting Stent with Abluminal Biodegradable Polymer in Real-World PracticeYoung Jin Youn, Sang Yong Yoo, Jun Won Lee, et al.
Circulation. Cardiovascular Interventions|March 13, 2020
Randomized Comparison of Everolimus- and Zotarolimus-Eluting Coronary Stents With Biolimus-Eluting Stents in All-Comer PatientsYoung Jin Youn, Jun-Won Lee, Sung Gyun Ahn, et al.
Korean Circulation Journal|December 29, 2024
Feasibility of Distal Radial Access in High Bleeding Risk Patients Who Underwent Percutaneous Coronary InterventionIn Tae Jin, Ji Woong Roh, Oh-Hyun Lee, et al.
Med (New York, N.Y.)|August 17, 2024
Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trialsYong-Joon Lee, Deok-Kyu Cho, Jun-Won Lee, et al.
The Korean Journal of Internal Medicine|July 9, 2023
Clinical safety and effectiveness of the Genoss drug-eluting stent in real-world clinical practiceYoung Jin Youn, Jun-Won Lee, Sung Gyun Ahn, et al.
Korean Circulation Journal|October 17, 2017
Clinical and Angiographic Outcomes of the First Korean-made Sirolimus-Eluting Coronary Stent with Abluminal Bioresorbable PolymerHyoung Mo Yang, Kyoung Woo Seo, Junghan Yoon, et al.
Clinical Therapeutics|August 1, 2021
Comparison of the Efficacy and Safety of Atorvastatin 40 mg/ω-3 Fatty Acids 4 g Fixed-dose Combination and Atorvastatin 40 mg Monotherapy in Hypertriglyceridemic Patients who Poorly Respond to Atorvastatin 40 mg Monotherapy: An 8-week, Multicenter, Randomized, Double-blind Phase III StudyJong Shin Woo, Soon Jun Hong, Dong Hoon Cha, et al.
Pageof 17